Next Article in Journal
Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–Resistant Patients: Recommendations and Evidence
Previous Article in Journal
Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 17
Issue 4
10.3747/co.v17i4.521
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Adjuvant Chemoradiation for Gastric Cancer with Infusional 5-Fluorouracil and Cisplatin: A Phase I Study

by
Zahra Kassam
1,2,*,
H. MacKay
2,3,
C. A. Buckley
1,
S. Fung
2,4,
M. Pintile
2,4,
A. Oza
2,3,
J. Brierley
1,2,
C. Swallow
2,5,
B. Cummings
1,2,
J. J. Knox
2,3,
J. Kim
1,2,
R. Wong
1,2,
L. Siu
2,3,
R. Feld
2,3 and
J. Ringash
1,2
1
Department of Radiation Oncology, Princess Margaret Hospital, 610 University Avenue, Toronto, ON M5G 2M9, Canada
2
University of Toronto, Toronto, ON, Canada
3
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
4
Department of Clinical Study Coordination and Biostatistics, Princess Margaret Hospital, Toronto, ON, Canada
5
Department of Surgical Oncology, Mount Sinai Hospital, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2010, 17(4), 34-41; https://doi.org/10.3747/co.v17i4.521
Submission received: 11 May 2010 / Revised: 9 June 2010 / Accepted: 7 July 2010 / Published: 1 August 2010

Abstract

Objective: This phase I study aimed to determine the maximal tolerated dose of cisplatin administered every 2 weeks with infusional 5-fluorouracil (5FU) and concurrent radiation therapy (RT) in patients after complete resection of gastric adenocarcinoma. Methods: Patients with resected stage IB to IV (M0) gastric adenocarcinoma were treated with 12 weeks of infusional 5FU (200 mg/m2 daily) and with RT (45 Gy in 25 fractions starting on day 16). Cisplatin was administered in escalating doses (0, 20, 30, and 40 mg/m2) in weeks 1, 3, 5, and 7. In the final cohort, patients received an additional dose of cisplatin (40 mg/m2) in week 9. Results: Among the 34 patients [median age: 56 years (range: 31–77 years)] who were assessable for toxicity, 5 experienced dose-limiting toxicities: 1 sepsis (cohort 1), 1 fatigue (cohort 2), 3 upper gastrointestinal toxicity (1 in cohort 2, 2 in cohort 5). Cohort 5 exceeded the maximal tolerated dose. Median follow-up was 2.5 years (range: 0.3–5 years). The 3-year overall and relapse-free survival rates were 86% and 71% respectively; median survival was not reached. Conclusions: Cisplatin was well tolerated in combination with infusional 5FU and RT, showing promising activity in the adjuvant treatment of gastric cancer. Infusional 5FU 200 mg/m2 daily for 12 weeks with cisplatin 40 mg/m2 in weeks 1, 3, 5, and 7 and with concurrent RT 45 Gy in 25 fractions, starting at day 16, is being explored in a phase II study at our institution.
Keywords: adjuvant therapy; chemoradiation; gastric cancer; phase i study; cisplatin; 5-fluorouracil adjuvant therapy; chemoradiation; gastric cancer; phase i study; cisplatin; 5-fluorouracil

Share and Cite

MDPI and ACS Style

Kassam, Z.; MacKay, H.; Buckley, C.A.; Fung, S.; Pintile, M.; Oza, A.; Brierley, J.; Swallow, C.; Cummings, B.; Knox, J.J.; et al. Adjuvant Chemoradiation for Gastric Cancer with Infusional 5-Fluorouracil and Cisplatin: A Phase I Study. Curr. Oncol. 2010, 17, 34-41. https://doi.org/10.3747/co.v17i4.521

AMA Style

Kassam Z, MacKay H, Buckley CA, Fung S, Pintile M, Oza A, Brierley J, Swallow C, Cummings B, Knox JJ, et al. Adjuvant Chemoradiation for Gastric Cancer with Infusional 5-Fluorouracil and Cisplatin: A Phase I Study. Current Oncology. 2010; 17(4):34-41. https://doi.org/10.3747/co.v17i4.521

Chicago/Turabian Style

Kassam, Zahra, H. MacKay, C. A. Buckley, S. Fung, M. Pintile, A. Oza, J. Brierley, C. Swallow, B. Cummings, J. J. Knox, and et al. 2010. "Adjuvant Chemoradiation for Gastric Cancer with Infusional 5-Fluorouracil and Cisplatin: A Phase I Study" Current Oncology 17, no. 4: 34-41. https://doi.org/10.3747/co.v17i4.521

APA Style

Kassam, Z., MacKay, H., Buckley, C. A., Fung, S., Pintile, M., Oza, A., Brierley, J., Swallow, C., Cummings, B., Knox, J. J., Kim, J., Wong, R., Siu, L., Feld, R., & Ringash, J. (2010). Adjuvant Chemoradiation for Gastric Cancer with Infusional 5-Fluorouracil and Cisplatin: A Phase I Study. Current Oncology, 17(4), 34-41. https://doi.org/10.3747/co.v17i4.521

Article Metrics

Back to TopTop